



University of Colorado **Anschutz Medical Campus**

mAb Colorado

Monoclonal Antibody Treatment for COVID-19: Ensuring Access for People who are Immunocompromised



Virtual Community Town Hall

October 19, 2021

AGENDA

6:00-6:05 Welcome

6:05-6:30 Panel Presentations



Dr. Adit Ginde
Emergency Medicine



Dr. Matthew Wynia
Internal Medicine

- Burden of COVID
- mAb Treatment for COVID

6:30-6:40 Community Member Stories



Betty Huart



David Legg

6:40-7:00 Q & A

7:00-7:30 Participant Feedback on Messaging

Panelists

Adit Ginde, MD, MPH

Matt Wynia, MD, MPH

Betty Huart, Special Guest

David Legg, Special Guest



COVID-19 and Immunosuppression

RISKS AND VACCINE EFFECTIVENESS

Causes of Immunosuppression

Health conditions

- Primary immunodeficiencies (rare)
- HIV infection
- Autoimmune conditions (RA, SLE, T1DM)
- Pregnancy
- Some cancers (leukemia, lymphoma)

Immune Suppressing Medications

- Systemic glucocorticoids: prednisone, dexamethasone, Medrol[®] etc.
- Transplant anti-rejection medications: Imuran[®], CellCept[®], Prograf[®], etc.
- Many cancer chemotherapies
- Rx for autoimmune conditions and severe allergies: Humira[®], Xeljanz[®], Rinvox[®], Enbrel[®], Remicade[®], Rituxan[®], Actemra[®], Kevzara[®]



Is risk of *severe* COVID-19 higher with immunosuppression?

Complex, but probably slightly higher risk of severe COVID-19

- 8 studies
- ~1.5-3x higher risk of severe COVID-19 disease for those who are immunocompromised

Severe disease =

- Acute respiratory distress syndrome (ARDS)
- Requiring life support
- Requiring mechanical ventilation
- Requiring intensive care unit (ICU) support




Vaccine effectiveness among immunocompromised people

Fully vaccinated people with immunosuppression still at risk for serious disease

- Vaccine effectiveness (mRNA vaccines): 62.9% for those with immunosuppression (vs 91.3%)

Solid organ transplants

- Experience immunosuppression due to use of anti-rejection drugs
- Weaker immune response to vaccines
- Benefit from a booster dose of vaccine
 - 40% have antibodies after the second dose
 - 68% have antibodies after the third dose (~1 month after the second)



Monoclonal Antibodies for COVID-19

Monoclonal Antibody (mAbs) Treatment for COVID-19


Laboratory-made human neutralizing IgG treatment to SARS-CoV-2

- Originally isolated from recovered patients

Binds to viral spike protein to block interaction with ACE2 receptor on host cells

Three treatments have Emergency Use Authorization

- Casirivimab/Imdevimab (Regeneron)
- Bamlanivimab/Etesivimab (Lilly)
- Sotrovimab (GSK)



Excerpt from mAb Colorado graphic novel
Credit Ion Medical Designs

COVID-19 mAbs Summary




<https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-the-prioritization-of-anti-sars-cov-2-mono-clonal-antibodies/>

- Multiple studies now show mAbs avert **70-80%** of hospitalizations and deaths
- mAbs can decrease symptoms by around **four days**
- Effective against **Delta variant**
- **Recommended by National Institutes of Health COVID-19 Treatment guidelines** for treatment of non-hospitalized people with mild to moderate symptoms of COVID-19 who are at high risk of severe disease, especially those who are immunocompromised
- mAbs can also be given as post-exposure prophylaxis

ANTIBODY TREATMENT TO PREVENT SEVERE COVID-19

ARE YOU ELIGIBLE?



YOU MAY BE ELIGIBLE


mAb
Colorado
[medschool.cuanschutz.edu/
mab-colorado](https://medschool.cuanschutz.edu/mab-colorado)

*ANY RISK CONDITIONS

- Older age — 65 years of age or older
- Obesity or being overweight — adults with body mass index of 25 or more, children in the 85th percentile for their age and gender based on CDC growth charts
- Pregnancy
- Chronic kidney disease
- Diabetes
- Immunosuppressive disease/ receiving immunosuppressive treatment
- Cardiovascular disease or hypertension
- Chronic respiratory disease
- Neurodevelopmental disorders
- Any other medical condition or factor — including race or ethnicity — associated with increased risk

For more information or to find an infusion center near you:
Call 1-877-332-6585 (English) or 1-877-366-0310 (Spanish), or visit combatcovid.hhs.gov.

mAb Eligibility Criteria

Use of mAbs in people with immunosuppression

- In a small group of 95 kidney transplant patients
 - 20 received mAbs: 15% were hospitalized or had an ER visit
 - 75 did not receive mAbs: 76% were hospitalized or had an ER visit
- PROVENT III trial of the AstraZeneca drug “AZD7442”
 - Intramuscular, long acting mAb—lasts ~9 months
 - Pre-Exposure Prophylaxis (prevention) for those at high risk for inadequate response to vaccine or high risk for severe disease
 - Reduced symptomatic COVID-19 by 77%
 - AstraZeneca has applied for Emergency Use Authorization

- Klein EJ, Hardesty A, Vieira K, Farmakiotis D. Use of anti-spike monoclonal antibodies in kidney transplant recipients with COVID-19: Efficacy, ethnic and racial disparities. *Am J Transplant*. 2021 Sep 30. doi: 10.1111/ajt.16843. Epub ahead of print. PMID: 34591350.
- <https://www.astrazeneca.com/media-centre/press-releases/2021/azd7442-prophylaxis-trial-met-primary-endpoint.html>



Did You Test Positive for COVID-19? **ACT FAST!**

You can feel better faster if you get an antibody treatment. It can help keep you out of the hospital.
It works best if you get it within the first few days after you have symptoms.

Find Out About Antibody Treatment. Take These Steps:

➔ **Call a Medical Provider Right Away**

- Call your primary care or urgent care provider.
- Tell them when you first had COVID-19 symptoms.
- Tell them if you have any other health problems.
- Ask them if they can help you get monoclonal antibody treatment.

➔ **Get a Referral to a Clinic**

If antibody treatment is right for you, the provider will make a referral to a clinic close to you where you can get the treatment. They will give you the address and phone number to the clinic.

**Many Health Plans Will
Pay the Full Cost of Treatment**

**Antibody Treatment
Works Against
the COVID-19 Delta Variant**



www.mAbColorado.org

How and where
do I get mAbs?

www.mAbColorado.org



We Need You

Our research team is currently conducting telephone surveys of patients who may have tested positive for COVID-19, and experienced symptoms where you would complete telephone surveys at 2 weeks, 4 weeks, and 3 months from the date you diagnosed with COVID-19.

Go to the [Participate in mAb Research page](#), click on "Request to take the survey" under the community members section.



Information for Patients

If you think you have COVID-19 or have tested positive, you may be eligible for monoclonal antibody (mAb) treatments. Find information here.



Information for Health Care Providers

Click here to find information about referring patients for monoclonal antibody (mAb) treatments for COVID-19.



Participate in mAb Research

Find information here about participating in research studies around access to and efficacy of monoclonal antibody (mAb) treatments for COVID-19.

Colorado COVID-19 Alert!

The Colorado Department of Public Health & Environment (CDPHE) has issued an urgent advisory regarding the increasing spread of the COVID-19 Delta variant in Colorado.

Community and Provider Messaging Kits

mAb Colorado
Colorado Clinical and Translational Sciences Institute


**Seeking mAb treatment?
Go here!**

Home | Info for Patients | Info for Health Care Providers | Research | Communication Kit | Contact | School of Medicine

Community Messaging Materials

See below for materials you can share with members of your organization or community about monoclonal antibody (mAb) treatments for COVID-19.

We are able to provide a limited number of printed materials mailed to you free-of-charge. If you would like to distribute printed materials to members of your organization or community, [complete this order form](#).




Download flyer with basic information about mAb treatments. Can be printed front-to-back.




Download document with answers to common questions about mAb treatments.




Download images to be shared as social media posts.



Download images to be shared as stories on Facebook or Instagram.



Download a half-page postcard with key points about mAb treatments.



Download the mAb Hero graphic novel which tells the patient story of monoclonal antibody treatment.

mAb Colorado
Colorado Clinical and Translational Sciences Institute

**Seeking mAb treatment?
Go here!**

Home | Info for Patients | Info for Health Care Providers | Research | Communication Kit | Contact | School of Medicine


Provider Messaging Materials

See below for materials that you can share with other health care providers or practices about monoclonal antibody (mAb) treatments for COVID-19.


We are able to provide a limited number of printed materials mailed to you free-of-charge. If you would like to distribute printed materials to members of your organization or community, [complete this order form](#).



Download flyer with a checklist for health care providers.



Download flyer with eligibility information about mAb treatments.



Download flyer that describes a clinic-based example of subcutaneous mAb treatments.

Please go to our website to order printed materials: <https://medschool.cuanschutz.edu/mab-colorado>



Questions? Comments?



www.mabcolorado.org

Adit.Ginde@cuanschultz.edu

Thank you!